Breast Carcinoma — Variants & evidence

Breast Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

156 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 151–156 of 156 evidence items (5 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TACSTD2 T256R1
Sacituzumab Govitecan	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Resistance	3	submitted	EID12265 TROP2 T256R mutation alters the plasma membrane localization and cell-surface binding of hRS7, the humanized antibody incorporated into Sacituzumab Govitecan (SG). The TROP2 T256R encoded protein was … (full text at CIViC) PMID 34404686 · Coates et al., 2021 · Open in CIViC	civic
High3
(diagnostic)	Breast Carcinoma	Diagnostic	B	Supports Positive	3	accepted	EID13105 Tumor mutational burden (TMB) derived from MSK-IMPACT targeted next-generation sequencing was evaluated in 7,894 breast cancers, from which 527 TMB-high tumors from 462 patients were identified. Tumor… (full text at CIViC) PMID 40775459 · Vougiouklakis et al., 2025 · Open in CIViC	civic
Immune Checkpoint Inhibitor	Triple-Negative Breast CarcinomaALIAS	Predictive	E	Supports N/A	3	submitted	EID12950 This review synthesizes current preclinical, translational, and clinical evidence evaluating tumor mutational burden (TMB) as a predictive biomarker for immune checkpoint inhibitor (ICI) response in t… (full text at CIViC) PMID 41249701 · Das et al., 2025 · Open in CIViC	civic
〃	Triple-Negative Breast CarcinomaALIAS
TOP1 -122fs + TOP1 E418K1
Sacituzumab Govitecan	Triple-Negative Breast CarcinomaALIAS	Predictive	C	Supports Resistance	3	submitted	EID12266 TOP1 E418K mutation and TOP1 122fs contribute to acquired resistance to Sacituzumab Govitecan (SG) therapy through alterations in the drug target TOP1. The patient, a 42-year-old female with metastati… (full text at CIViC) PMID 34404686 · Coates et al., 2021 · Open in CIViC	civic
ORC1 Mutation + XRCC3 MutationXRCC3 ORC11
Cisplatin	Triple-Negative Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID11716 In this study, the sensitivity to Cisplatin (a platinum-based drug) was studied in XRCC3 knockout, and ORC1 mutant PDX models. A role of XRCC3 loss in cisplatin sensitivity was reported in the study. … (full text at CIViC) PMID 37029129 · Ter Brugge et al., 2023 · Open in CIViC	civic

Data updated 10 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.